Incannex Healthcare Limited (IHL:ASX)


right-arrow Created with Sketch. 0.005 (1.41%)
MCAP $429.0M
Last trade 16.10pm 19/10/2021 20mins delayed

Latest Announcements

11/10/2021IHLIncannex Healthcare Limited
08/10/2021IHLIncannex Healthcare Limited
07/10/2021IHLIncannex Healthcare Limited
07/10/2021IHLIncannex Healthcare Limited
06/10/2021IHLIncannex Healthcare Limited
04/10/2021IHLIncannex Healthcare Limited
04/10/2021IHLIncannex Healthcare Limited
04/10/2021IHLIncannex Healthcare Limited

Company Overview

Incannex Healthcare Limited is an Australia-based company. It is a clinical stage pharmaceutical development company. The Company is engaged in developing medicinal cannabis pharmaceutical products and psychedelic medicine therapies. Its product candidate IHL-42X is developing a combination of acetazolamide and dronabinol to reduce the apnea hypopnea index (AHI), IHL-216A is a combination of isoflurane and CBD to prevent development of traumatic brain injury (TBI)/concussion, HL-675A comprises a combination of hydroxychloroquine and CBD in prevention and treatment of inflammatory lung conditions (ARDS, COPD, asthma, and bronchitis), rheumatoid arthritis and inflammatory bowel diseases and Psi-GAD is providing Psychedelic-assisted psychotherapy for Generalized Anxiety Disorder (GAD).

IHL in the news

Incannex Healthcare (IHL) files a registration statement with the US Securities and…
Incannex Healthcare (IHL) partners with Monash University to study a treatment for…
Incannex Healthcare (IHL) spends the fourth quarter progressing its cannabinoid pharmaceutical products…
Incannex Healthcare (IHL) commences its phase one human clinical trial to assess…

Search Previous Announcements